AAO 2023: Novel Cell Therapy May Aid Macular Telangiectasia Type 2
Significant benefit seen for primary end point, rate of ellipsoid zone area loss from baseline through month 24
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.